Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell ...

Approximately 213,380 new cases of non-small-cell ... between two receptors within the cell membrane, and an intracellular domain that contains the tyrosine kinase enzymatic activity.

Department of Biomedical Engineering, University of West Attica, Ag. Spyridonos, Egaleo 12243, Greece ...

Advanced non-small-cell lung cancer ... pathways downstream of activated erbB receptor tyrosine kinases. The Ras–MAPK (mitogen-activated protein kinase) pathway is another important cell ...

and proline-rich tyrosine kinase-2 (Pyk2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and Pyk2 integrate signals from integrin and growth ...

FIGURE 1. Different structural types of small-molecule MET kinase inhibitors. We focused on the design of new antiproliferative agents with potential interactions with MET active site as type II ...